The Economic Costs of Alcohol and Drug Abuse in the United States - 1992
Table 4.19
Treatment Costs per Acute Hepatitis B Virus Case
| Disease Stages/Conditions |
Probability of Stage
(%) |
Number of Cases in 1992 |
Cost per Case in 1992
(dollars) |
Total HBV Treatment Expenditures
(millions of dollars) |
Total IVDU-Related HBV Expenditures
(millions of dollars) |
| Acute Disease Only |
| Subclinical |
65.7 |
131,400 |
$6 |
$0.8 |
$0.1 |
| Clinical, nonfulminant |
34.0 |
68,000 |
$703 |
$47.8 |
$5.7 |
| Fulminant |
0.3 |
600 |
$12,124 |
$7.2 |
$0.9
|
| Subtotal, Acute |
100.0 |
200,000 |
NA |
$55.9 |
$6.7 |
| Chronic Disease |
| Chronic carrier state |
3.9 |
2,657 |
$950 |
$2.5 |
$0.3 |
| Chronic persistent state |
2.0 |
1,363 |
$1,618 |
2.2 |
$0.3 |
| Chronic active hepatitis |
2.6 |
1,771 |
$67,486 |
$119.6 |
$14.3 |
| Primary hepatic cancer |
1.3 |
886 |
$103,148 |
$91.4 |
$11.0 |
| Subtotal, Chronic |
6-10 |
6,677 |
NA |
$215.6 |
$25.9 |
| Total, All Conditions |
$271.5 |
$32.6 |
Source: Bloom et al. (1993).
Note: Components may not sum to totals because of rounding. Intravenous drug use is estimated to cause 12 percent of hepatitis B (HBV) cases.
|
